NYSE:PKI - PerkinElmer Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$82.07 -2.99 (-3.52 %)
(As of 11/12/2018 04:00 PM ET)
Previous Close$85.06
Today's Range$81.98 - $84.91
52-Week Range$69.21 - $98.33
Volume705,627 shs
Average Volume648,695 shs
Market Capitalization$9.46 billion
P/E Ratio28.30
Dividend Yield0.33%
Beta1.11
PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers analytical technologies, solutions, and services for the environmental market that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. It also provides solutions to farmers and food producers; an analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries; and laboratory services. In addition, this segment offers a suite of solutions comprising reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market. The Diagnostics segment provides instruments, reagents, and software test and screen products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used in diagnosing genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for use in applications covering oncology, genetic testing, and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. has a collaboration agreement with Helix and PerkinElmer. The company was founded in 1931 and is headquartered in Waltham, Massachusetts.

Receive PKI News and Ratings via Email

Sign-up to receive the latest news and ratings for PKI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorComputer and Technology
Current SymbolNYSE:PKI
Previous Symbol
CUSIP71404610
Phone781-663-6900

Debt

Debt-to-Equity Ratio0.73
Current Ratio1.70
Quick Ratio1.18

Price-To-Earnings

Trailing P/E Ratio28.30
Forward P/E Ratio22.80
P/E Growth1.9

Sales & Book Value

Annual Sales$2.26 billion
Price / Sales4.04
Cash Flow$3.7855 per share
Price / Cash21.68
Book Value$23.13 per share
Price / Book3.55

Profitability

EPS (Most Recent Fiscal Year)$2.90
Net Income$292.63 million
Net Margins4.71%
Return on Equity15.04%
Return on Assets6.35%

Miscellaneous

Employees11,000
Outstanding Shares111,240,000
Market Cap$9.46 billion
OptionableOptionable

PerkinElmer (NYSE:PKI) Frequently Asked Questions

What is PerkinElmer's stock symbol?

PerkinElmer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PKI."

How often does PerkinElmer pay dividends? What is the dividend yield for PerkinElmer?

PerkinElmer declared a quarterly dividend on Wednesday, October 24th. Investors of record on Friday, January 18th will be given a dividend of $0.07 per share on Friday, February 8th. This represents a $0.28 dividend on an annualized basis and a yield of 0.34%. The ex-dividend date of this dividend is Thursday, January 17th. View PerkinElmer's Dividend History.

How were PerkinElmer's earnings last quarter?

PerkinElmer, Inc. (NYSE:PKI) released its earnings results on Wednesday, October, 31st. The medical research company reported $0.90 earnings per share for the quarter, missing the consensus estimate of $0.92 by $0.02. The medical research company earned $674.30 million during the quarter, compared to the consensus estimate of $676.72 million. PerkinElmer had a net margin of 4.71% and a return on equity of 15.04%. The business's revenue was up 21.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.73 EPS. View PerkinElmer's Earnings History.

When is PerkinElmer's next earnings date?

PerkinElmer is scheduled to release their next quarterly earnings announcement on Thursday, January 24th 2019. View Earnings Estimates for PerkinElmer.

What guidance has PerkinElmer issued on next quarter's earnings?

PerkinElmer issued an update on its FY18 earnings guidance on Wednesday, October, 31st. The company provided earnings per share (EPS) guidance of ~$3.60 for the period, compared to the Thomson Reuters consensus estimate of $3.66. PerkinElmer also updated its FY 2018 guidance to $3.60-3.60 EPS.

What price target have analysts set for PKI?

10 analysts have issued 12-month target prices for PerkinElmer's shares. Their predictions range from $73.36 to $100.00. On average, they anticipate PerkinElmer's stock price to reach $88.1511 in the next twelve months. This suggests a possible upside of 7.4% from the stock's current price. View Analyst Price Targets for PerkinElmer.

What is the consensus analysts' recommendation for PerkinElmer?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PerkinElmer in the last year. There are currently 7 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for PerkinElmer.

Has PerkinElmer been receiving favorable news coverage?

Media stories about PKI stock have been trending somewhat positive this week, InfoTrie Sentiment reports. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. PerkinElmer earned a media sentiment score of 1.5 on InfoTrie's scale. They also assigned media coverage about the medical research company a news buzz of 7.0 out of 10, meaning that recent news coverage is likely to have an impact on the company's share price in the near term.

Who are some of PerkinElmer's key competitors?

Who are PerkinElmer's key executives?

PerkinElmer's management team includes the folowing people:
  • Mr. Robert F. Friel, Chairman, CEO & Pres (Age 62)
  • Mr. Joel S. Goldberg, Sr. VP of Admin., Gen. Counsel & Sec. (Age 49)
  • Mr. James Corbett, Exec. VP & Pres of Discovery and Analytical Solutions (Age 55)
  • Mr. Prahlad R. Singh, Exec. VP & Pres of Diagnostics (Age 53)
  • Mr. James M. Mock, Sr. VP & CFO

Who are PerkinElmer's major shareholders?

PerkinElmer's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.89%), Janus Henderson Group PLC (5.61%), Massachusetts Financial Services Co. MA (3.08%), FMR LLC (1.26%), Bank of New York Mellon Corp (0.74%) and Fisher Asset Management LLC (0.43%). Company insiders that own PerkinElmer stock include Alexis P Michas, Andrew Okun, Daniel R Tereau, Deborah A Butters, Frank Anders Wilson, James Corbett, Joel S Goldberg, Nicholas A Lopardo, Patrick J Sullivan, Peter Barrett, Prahlad R Singh, Robert F Friel and Vicki L Sato. View Institutional Ownership Trends for PerkinElmer.

Which institutional investors are selling PerkinElmer stock?

PKI stock was sold by a variety of institutional investors in the last quarter, including Robecosam AG, Janus Henderson Group PLC, First Trust Advisors LP, JPMorgan Chase & Co., Tributary Capital Management LLC, Public Employees Retirement Association of Colorado, Daiwa Securities Group Inc. and Ontario Teachers Pension Plan Board. Company insiders that have sold PerkinElmer company stock in the last year include Alexis P Michas, Andrew Okun, Daniel R Tereau, Deborah A Butters, Frank Anders Wilson, James Corbett, Joel S Goldberg, Nicholas A Lopardo, Patrick J Sullivan, Peter Barrett and Robert F Friel. View Insider Buying and Selling for PerkinElmer.

Which institutional investors are buying PerkinElmer stock?

PKI stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, BlackRock Inc., State Treasurer State of Michigan, Massachusetts Financial Services Co. MA, Assenagon Asset Management S.A., Artemis Investment Management LLP, WINTON GROUP Ltd and Bank of Montreal Can. View Insider Buying and Selling for PerkinElmer.

How do I buy shares of PerkinElmer?

Shares of PKI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is PerkinElmer's stock price today?

One share of PKI stock can currently be purchased for approximately $82.07.

How big of a company is PerkinElmer?

PerkinElmer has a market capitalization of $9.46 billion and generates $2.26 billion in revenue each year. The medical research company earns $292.63 million in net income (profit) each year or $2.90 on an earnings per share basis. PerkinElmer employs 11,000 workers across the globe.

What is PerkinElmer's official website?

The official website for PerkinElmer is http://www.perkinelmer.com.

How can I contact PerkinElmer?

PerkinElmer's mailing address is 940 WINTER STREET, WALTHAM MA, 02451. The medical research company can be reached via phone at 781-663-6900 or via email at [email protected]


MarketBeat Community Rating for PerkinElmer (NYSE PKI)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  392 (Vote Outperform)
Underperform Votes:  404 (Vote Underperform)
Total Votes:  796
MarketBeat's community ratings are surveys of what our community members think about PerkinElmer and other stocks. Vote "Outperform" if you believe PKI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PKI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/12/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel